The Risk of XXXX in @entity1 With Type 2 Diabetes: Associations With Treatment Stage and Obesity.

@entity1 @entity28 @entity6 @entity164 @entity14
OBJECTIVE: To assess the risk of @entity14 associated with @entity164 2 @entity6 , as compared with a nondiabetic reference population, and to study additional associations between treatment stage and duration of @entity28 and @entity14 risk. RESEARCH DESIGN AND METHODS: We conducted an observational population-based cohort study within the Clinical Practice Research Datalink (1987-2012). All @entity1 (>= 18 years) with at least one prescription for an antidiabetic drug (n = 300,039) were matched (1:1) by birth year, sex, and practice to a comparison cohort without @entity6 . Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) for @entity14 associated with @entity164 2 @entity6 . Within the @entity6 cohort, associations of @entity14 with treatment stages and duration of @entity28 (BMI >= 30 kg/m(2)) were studied. RESULTS: After a median follow-up of 4.5 years, 2,759 cases of @entity14 were observed among the @entity6 study population. @entity164 2 @entity6 was associated with a 1.3-fold increased risk of @entity14 (HR 1.26 [95% CI 1.18-1.33]). Among @entity6 @entity1 , no association was found with treatment stages. A trend of increased @entity14 risk was observed with longer duration of @entity28 . Risk of @entity14 was significantly increased for @entity1 with recorded duration of @entity28 of 4-8 years (HR 1.19 [1.06-1.34]) and >8 years (1.28 [1.11-1.49]). CONCLUSIONS: @entity164 2 @entity6 is associated with a moderately increased risk of @entity14 . Among @entity6 @entity1 , an increased risk was observed for @entity1 who suffered from @entity28 for a total duration of 4 years or more.
